Gitelman syndrome combined with complete growth hormone deficiency

Area of Science:

• Nephrology
• Genetics
• Pediatrics

Background:

• Gitelman syndrome is a rare autosomal recessive salt-losing tubulopathy.
• It is characterized by hypokalemic metabolic alkalosis, hypomagnesemia, and hypocalciuria.
• Mutations in the SLC12A3 gene encoding the thiazide-sensitive sodium chloride cotransporter cause Gitelman syndrome.

Purpose of the Study:

• To report a case of Gitelman syndrome presenting with short stature and hypokalemic metabolic alkalosis.
• To investigate the potential link between Gitelman syndrome and growth hormone deficiency.
• To evaluate the efficacy of growth hormone treatment in a patient with Gitelman syndrome and growth hormone deficiency.

Main Methods:

• Case report of a 12.9-year-old girl with short stature and hypokalemic metabolic alkalosis.
• Genetic testing revealed a heterozygous mutation in the SLC12A3 gene.
• Growth hormone (GH) provocative tests indicated complete GH deficiency.

Main Results:

• The patient was diagnosed with Gitelman syndrome and complete GH deficiency.
• Treatment with GH, magnesium oxide, and potassium replacement led to a positive clinical response.
• Growth acceleration was observed following GH therapy.

Conclusions:

• Gitelman syndrome can be associated with growth retardation and growth hormone deficiency.
• Combined treatment with GH and electrolyte replacement is effective in managing Gitelman syndrome with growth issues.
• This case underscores the importance of considering endocrine disorders in patients with Gitelman syndrome and short stature.